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Abstract
Lung cancer remains the leading cause of cancer-related deaths worldwide, and non-small cell lung cancer (NSCLC)
represents approximately 80% of total lung cancer cases. The use of non-toxic dietary phytochemicals can be considered as
a chemotherapeutic strategy for the management of the NSCLC. Here, we report that grape seed proanthocyanidins (GSPs)
induce apoptosis of NSCLC cells, A549 and H1299, in vitro which is mediated through increased expression of pro-apoptotic
protein Bax, decreased expression of anti-apoptotic proteins Bcl2 and Bcl-xl, disruption of mitochondrial membrane
potential, and activation of caspases 9, 3 and poly (ADP-ribose) polymerase (PARP). Pre-treatment of A549 and H1299 cells
with the caspase-3 inhibitor (z-DEVD-fmk) significantly blocked the GSPs-induced apoptosis of these cells confirmed that
GSPs-induced apoptosis is mediated through activation of caspases-3. Treatments of A549 and H1299 cells with GSPs
resulted in an increase in G1 arrest. G0/G1 phase of the cell cycle is known to be controlled by cyclin dependent kinases
(Cdk), cyclin-dependent kinase inhibitors (Cdki) and cyclins. Our western blot analyses showed that GSPs-induced G1 cell
cycle arrest was mediated through the increased expression of Cdki proteins (Cip1/p21 and Kip1/p27), and a simultaneous
decrease in the levels of Cdk2, Cdk4, Cdk6 and cyclins. Further, administration of 50, 100 or 200 mg GSPs/kg body weight of
mice by oral gavage (5 d/week) markedly inhibited the growth of s.c. A549 and H1299 lung tumor xenografts in athymic
nude mice, which was associated with the induction of apoptotic cell death, increased expression of Bax, reduced
expression of anti-apoptotic proteins and activation of caspase-3 in tumor xenograft cells. Based on the data obtained in
animal study, human equivalent dose of GSPs was calculated, which seems affordable and attainable. Together, these
results suggest that GSPs may represent a potential therapeutic agent for the non-small cell lung cancer.
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Introduction
Lung cancer remains the leading cause of cancer related deaths
in the United States and worldwide [1]. One of every three cancer-
related deaths is attributable to lung cancer, and the dismal 5-year
survival rate of approximately 14% has shown no improvement
over the past three decades [2,3]. Small-cell lung cancer and non-
small-cell lung cancer (NSCLC) account for 90% of all lung
cancers. NSCLC represents approximately 80% of all types of
lung cancer and includes squamous cell carcinomas, adenocarci-
nomas, and large-cell carcinomas [4,5]. Although a combination
of chemotherapy and radiation therapy can improve survival of
the patients, most patients die of disease progression, often
resulting from acquired or intrinsic resistance to chemotherapeutic
drugs [6]. Therefore, the exploration and development of more
effective therapeutic agents and therapies that can target the
molecules associated with tumor growth and apoptosis resistance
will lead to improved outcomes in patients with lung cancer.
Natural plant products offer promising new options for the
development of more effective chemotherapeutic strategies for
cancers of various organs. Grape seed proanthocyanidins (GSPs)
are promising phytochemicals that have anti-inflammatory [7] and
anti-oxidant properties [8–10], and appear to exhibit minimal
toxicity in laboratory animals [9,10]. GSPs are readily extracted
from grape-seeds, a by-product of grape juice and wine industries,
and are a mixture of several polyphenolic components, which
constitute dimers, trimers, tetramers, and oligomers/polymers of
monomeric catechins and/or (-)-epicatechins, as described previ-
ously [9,10]. We believe that at least some of the constituents
present in GSPs act synergistically and may provide better
chemotherapeutic effects than a single constituent.
Previously, we have shown that dietary supplementation of
GSPs with AIN76A control diet resulted in a dose-dependent
inhibition of the growth of A549 and H1299 NSCLC tumor
xenograft in athymic nude mice, and the growth inhibitory effect
of GSPs on the NSCLC xenograft tumors was associated with the
enhancement of the levels of insulin-like growth factor binding
protein-3 and anti-angiogenic effects in the tumor microenviron-
ments (11). In another study, we also have reported that GSPs
inhibit the proliferation and induce apoptosis of NSCLC cells in
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inhibitory effects on the cyclooxygenase-2 expression and
production of its prostaglandin metabolite, PGE2 (12). In contrast,
a significant inhibition of cell proliferation and induction of
apoptosis in normal human bronchial epithelial cells after GSPs
treatment under identical conditions was not observed [11,12]. In
spite of anti-carcinogenic effects of GSPs on NSCLC cells, a
precise mechanism of the inhibitory effect on the NSCLC cell
growth and apoptosis by GSPs is not well understood. In the
present communication, we conducted a comprehensive investi-
gation on the mechanism responsible for the inhibition of lung
cancer cell proliferation and apoptosis using A549 and H1299 cell
lines as an in vitro cell culture model and in vivo tumor xenograft
model. To study the in vivo effect of GSPs on tumor xenograft
growth, GSPs was given to mice by oral gavage 5 days/week. We
report that GSPs-induced apoptotic cell death of NSCLC cells is
mediated through modulations in the expression levels of pro- and
anti-apoptotic proteins, loss of mitochondrial membrane potential
and caspase-3 activation pathways. GSPs also checked the
deregulated cell cycle progression and associated regulatory
proteins in NSCLC cells. Thus our studies provide insight into
the mechanism by which GSPs induce apoptosis in these cells.
Additionally, our results provide a convincing rationale for the
pharmacological activity of GSPs against human non-small cell
lung cancer cells.
Materials and Methods
Reagents, chemicals and antibodies
The GSPs used in this study were obtained from Kikkoman
Corporation (Noda, Japan). The JC-1 Mitochondrial Membrane
Potential Detection Kit, and Anti-OxPhos Complex IV subunit IV
(Cox IV) were purchased from Molecular Probes, Inc. (Eugene,
OR). Cell Death Detection ELISA Kits were obtained from Roche
Diagnostic Corporation (Indianapolis, IN). The primary antibod-
ies were purchased as follows: antibodies for Bcl-2, Bcl-xl, Bax,
caspase-9, cleaved caspase-9 and -3, anti-poly(ADP-ribose)
polymerase (PARP) and b-actin were purchased from Cell
Signaling Technology (Beverly, MA); antibodies for cytochrome
c, Smac/DIABLO, Cyclin D1, Cyclin D2, Cyclin E, Cdk2, Cdk4,
Cdk6, Cip1/p21, Kip1/p27 and the secondary antibodies,
horseradish peroxidase-linked antimouse immunoglobulin G and
anti-rabbit immunoglobulin G were obtained from Santa Cruz
Biotechnology, Inc. (Santa Cruz, CA). Caspase-3-specific inhibitor
(z-DEVD-fmk) was purchased from Calbiochem (San Diego, CA).
ApoTarget Kit specific to caspase-3 activity assay was obtained
from BioSource International, Inc. (San Diego, CA). Ham’s F-12,
RPMI 1640, penicillin, streptomycin and trypsin/EDTA were
obtained from Cellgro (Herndon, VA). The enhanced chemilu-
minescence western blotting detection reagents were purchased
from Amersham Pharmacia Biotech (Piscataway, NJ).
Cell culture and cell lines
Human non-small cell lung carcinoma cell lines, A549 and
H1299, and normal human bronchial epithelial cells were
purchased from the American Type Culture Collection (Manassas,
VA). The A549 and H1299 cell lines were cultured as monolayers
in Ham’s F-12 and RPMI 1640 culture medium, respectively,
supplemented with 10% heat-inactivated fetal bovine serum
(Hyclone, Logan, UT), 100 mg/mL penicillin, and 100 mg/mL
streptomycin and maintained in an incubator with a humidified
atmosphere of 95% air and 5% CO2 at 37uC. The GSPs were
dissolved in a small amount of dimethylsulfoxide [DMSO,
maximum concentration, 0.1% (v/v)], which was then added to
complete cell culture medium prior to addition to subconfluent
cells (60–70% confluent). Cells treated with vehicle only (DMSO,
0.1% in media) served as control.
Analysis of apoptotic cell death by ELISA
Cells were treated with GSPs for 48 h and thereafter harvested.
GSPs-induced apoptosis was determined using the Cell Death
Detection ELISA Kit (Roche Diagnostics, Palo Alto, CA), which
quantifies cytoplasmic histone-associated DNA fragments in the
form of mononucleosomes or oligonucleosomes, following the
manufacturer’s instructions.
Caspase-3 activity assay
The activity of caspase-3 in cell lysates was measured using the
colorimetric protease assay ApoTarget Kit (BioSource Interna-
tional, Inc., CA) following the manufacturer’s protocol. Briefly,
A549 or H1299 cells were treated with GSPs (20, 40, 60 and
80 mg/mL) for 48 h. Thereafter, the cells were harvested using
short trypsinization and cell lysates prepared following the
manufacturer’s protocol. Samples of the cell lysates (100 mg
protein per sample) were mixed with reaction buffer and
200 mmol/L substrate (DEVD-pNA for caspase-3) and incubated
for 3 h at 37uC in the dark. The absorbance was then measured at
405 nm and the sample readings calculated by subtracting the
absorbance of blank samples.
DNA cell cycle analysis
Sub-confluent cells (50–60%) were treated with varying
concentrations of GSPs in complete medium for 48 h. The cells
were then harvested, washed with cold PBS, and processed for cell
cycle analysis, as detailed previously [13,14]. Briefly, the cells
(1610
5) were re-suspended in 50 mL cold PBS to which 450 mL
cold methanol was added and the cells were then incubated for 1 h
at 4uC. The cells were centrifuged at 1,100 rpm for 5 minutes; the
pellet was washed with cold PBS, re-suspended in 500 mL PBS,
and incubated with 5 mL RNase (20 mg/mL final concentration)
for 30 minutes. The cells were incubated with propidium iodide
(50 mg/mL) on ice for 1 h in the dark. The cell cycle distribution
of the cells was then determined using FACSCalibur instrument
(BD Biosciences, San Jose, CA) equipped with CellQuest 3.3
software in the Fluorescence-activated Cell Sorting (FACS)
machine at the Core Facility of the UAB Comprehensive Cancer
Center.
Immunoprecipitation and western blot analysis
Following treatment of A549 and H1299 cells with GSPs, the
cells were harvested, washed with cold PBS and lysed with ice-cold
lysis buffer supplemented with protease inhibitors, as detailed
previously [12,13]. For immunoblotting of cytochrome c, Smac/
DIABLO and Cox IV, mitochondrial and cytosolic fractions were
prepared from the cells and the proteins were resolved on 10%
Tris-Glycine gels and transferred onto a nitrocellulose membrane.
After blocking the non-specific binding sites, the membrane was
incubated with the desired primary antibody at 4uC overnight.
The membrane was then incubated with appropriate peroxidase-
conjugated secondary antibody and the immunoreactive bands
were visualized using the enhanced chemiluminescence reagents.
Each membrane was stripped and re-probed with anti-b-actin
antibody to ensure equal protein loading.
For Cdk inhibitor (Cdki)-Cdk binding assay, A549 cells were
treated with vehicle or 60 mg/mL GSPs for 48 h, washed with ice-
cold PBS, and whole cell lysates prepared as described previously
[13]. Aliquots containing 200 mg of protein were cleared with
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Kip1/p27 proteins were immunoprecipitated from whole cell
lysates using specific antibodies after incubation for 8 h followed
by the addition of protein A/G-plus agarose beads (50 mL, Santa
Cruz, CA) and continued incubation overnight at 4uC. Immuno-
precipitates were washed, and subsequently subjected to western
blot analysis using Tris-Glycine gels followed by immunoblotting
using Cdk2, Cdk4 and Cdk6 antibodies.
Assay for mitochondrial membrane potential
The change in the mitochondrial membrane potential in lung
cancer cells after treatment with GSPs was determined by flow
cytometry using the fluorescent lipophilic cationic probe JC-1
(5,59,6,69-tetrachloro-1,19,3,39-tetraethylbenzimidazolcarbocyanine
iodide) Detection Kit following the instructions of the manufacturer,
and as described by us previously [13,14]. JC-1 accumulates
selectivelywithinintactmitochondriatoform multimerJ-aggregates
emitting fluorescence light at 590 nm. The monomeric form emits
light at 527 nm after excitation at 490 nm. Thus, the color of the
dye changes from orange to green, depending on the mitochondrial
membrane potential, and can be analyzed by FACS with green
fluorescence in channel 1 (FL1) and orange emission in channel 2
(FL2).
Animals and tumor xenograft study
Female athymic nude mice (4–5 weeks-old) were purchased
from National Cancer Institute (Frederick, MD), housed in
accordance with the Institutional Animal Care and Use Commit-
tee guidelines, and provided with sterilized AIN76A diet and water
ad libitum. All mice were maintained under standard conditions of a
12-h dark/12-h light cycle, a temperature of 2462uC, and relative
humidity of 50610%. The animal protocol used in this study was
approved by the Institutional Animal Care and Use Committee of
the University of Alabama at Birmingham, and approved Animal
Protocol Number is: 101109267.
To determine the in vivo efficacy of GSPs against human lung
cancer tumor xenograft growth, exponentially growing A549 and
H1299 cells (2610
6) were mixed at a 1:1 ratio with Matrigel
(Becton Dickinson, Bedford, MA), and a 100 mL suspension
containing 2610
6 cells was injected s.c. in the right flank of each
mouse. After 24 h, mice were randomly divided in four groups
(n=10). Experimental animals were treated by oral gavage with
50, 100 or 200 mg GSPs/kg body weight/day in 100 mL of PBS
five-days a week (Monday through Friday) beginning one day after
tumor cell implantation. Control mice received an equal volume of
PBS. The experiment was terminated 58 days after tumor cell
inoculation. Tumor growth was monitored 2-times per week. Body
weight/mouse and diet consumption/mouse were recorded
regularly throughout the experiment. Animals were also moni-
tored if they become ill or suffering (lack normal grooming and
avoidance behaviors) during the entire experiment period. At the
termination of the experiment, the whole tumor mass was
harvested, weighed, and a part of the tumor was used for the
preparation of tumor lysates to analyze the expression levels of
different proteins of interest and remaining part was used for
immunohistochemical analysis.
Immunohistochemical detection of PCNA-positive and
TUNEL-positive cells
Five-mm thick tumor sections were deparaffinized and rehy-
drated in a graded series of alcohols. Following rehydration, an
antigen retrieval process was performed by placing the slides in
10 mM sodium citrate buffer, pH 6.0 at 95uC for 20 minutes
followed by 20-minutes cooling. The sections were washed in PBS
and non-specific binding sites were blocked with 1% BSA with 2%
goat serum in PBS prior to incubation with anti-PCNA antibodies
for 2 h at room temperature. After washing, the sections were
incubated with biotinylated secondary antibody for 45 min
followed by HRP-conjugated streptavidin, washing in PBS,
incubation with diaminobenzidine substrate, and counterstaining
with hematoxylin. Apoptotic cell death in tumor tissues was
detected using terminal deoxynucleotidyl transferase-mediated
dUTP nick-end labeling (TUNEL) assays. The numbers of PCNA-
positive and TUNEL-positive cells were detected and counted
using a light microscope. The results are presented as the number
of positive cells x 100/total number of cells.
Statistical analysis
The results from the in vivo studies are representative of at least
2–3 independent experiments. The statistical significance of
difference between control and GSPs-treated groups were
calculated by Student’s t test (Sigma Stat 2.03, Jandel Scientific,
San Rafael, CA). All quantitative data are shown as mean 6 SD.
In tumor xenograft study, the statistical significance of difference
between control and GSPs-treated groups was determined by
ANOVA followed by Bonferroni t test, and in each case P,0.05
was considered statistically significant.
Results
NSCLC cells are sensitive to GSPs-induced apoptosis
We have shown that treatment of A549 and H1299 NSCLC
cells with various concentrations of GSPs inhibits the growth or
proliferation potential of these cells in a dose- and time-dependent
manner. GSPs also induced apoptotic cell death of these cells in a
concentration dependent manner [11,12]. The GSPs-induced
apoptosis of A549 and H1299 cells after treatment for 48 h using
FACS analysis is summarized in Figure 1A. However, a precise
mechanism of anti-apoptotic effects of GSPs against NSCLC cells
is not clearly understood. Therefore, the studies were conducted to
determine the precise mechanism involved in apoptotic cell death
of NSCLC cells by the treatment with GSPs.
GSPs reduce the expression of the anti-apoptotic
proteins Bcl-xl and Bcl-2 while increasing the expression
of pro-apoptotic protein Bax in A549 and H1299 cells
The proteins of the Bcl-2 family play a major role in regulation
of apoptosis by functioning as promoters (e.g., Bax) or inhibitors
(Bcl-2 or Bcl-xl) of cell death [15–17]. Using western blot analysis,
we found that treatment of A549 and H1299 cells with GSPs for
48 h resulted in a dose-dependent reduction in the levels of the
anti-apoptotic proteins Bcl-xl and Bcl-2, and an increase in the
levels of the pro-apoptotic protein, Bax, as compared with the
vehicle-treated control cells (Figure 1 B). Thus, treatment of these
lung cancer cells with GSPs can alter the protein levels of key
members of the Bcl-2 family in a manner that favors an increase in
the ratio of Bax: Bcl-2, which may contribute to the susceptibility
of cancer cells to GSP-induced apoptosis [15].
GSPs induce loss of mitochondrial membrane potential
and a subsequent enhancement of the release of
cytochrome c and Smac/DIABLO in NSCLC cells
Loss of mitochondrial membrane potential has been linked to
the initiation and activation of apoptotic process in cells [15,16].
The release of cytochrome c and Smac/DIABLO from mito-
chondria into the cytosol contributes to the activation of caspases
Proanthocyanidins Inhibit Growth of Lung Cancer
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effects of GSPs on this process in the A549 and H1299 cells,
cytosolic and mitochondrial fractions were prepared from cells
that had been treated with GSPs for 48 h. The results of western
blot analysis revealed that treatment of GSPs resulted in a dose-
dependent increase in cytochrome c and Smac/DIABLO release
into the cytosol and a corresponding reduction in the levels of
cytochrome c and Smac/DIABLO in the mitochondrial fractions
in both A549 and H1299 cells (Fig. 2A and 2B), thus suggesting
the loss of the mitochondrial membrane potential on GSPs
treatment in these cells. The blots were stripped and re-probed
with anti-COX IV antibody to rule out the possibility of cross-
contamination of mitochondrial and cytosolic fractions. The
presence of COX IV was not detected in cytosolic fractions.
To further verify that GSPs induce a loss of mitochondrial
membrane potential, we used the cationic lipophilic dye, JC-1,
which accumulates within mitochondria in a potential-dependent
manner. On disruption of the mitochondrial membrane potential,
the fluorescence emission of JC-1 dye changes from red to green.
Forty-eight h after the addition of the GSPs, the A549 and H1299
cells were harvested, incubated with JC-1 dye and the fluorescence
emission analyzed using flow cytometry. As shown in Figure 2C,
GSP treatment of A549 and H1299 cells resulted in a dose-
dependent increase in the numbers of green-fluorescence-positive
cells, as shown in the lower right (LR) quadrant of the FACS
histogram. Collectively, these studies suggest that GSPs treatment
induce apoptosis of both A549 and H1299 lung carcinoma cells
through disruption of the mitochondrial membrane potential.
GSPs induce the activation of caspases and PARP in both
A549 and H1299 cells
The release of the cytochrome c and Smac/DIABLO into
cytosol activates procaspase 9 in the apoptosome and leads to
active caspase-9 cleavage and cleavage of caspase-3 [18–20].
Activation of caspase-3 subsequently leads to apoptotic cell death
through cleavage of a broad spectrum of target proteins including
PARP. Therefore, we determined whether induction of apoptosis
of A549 and H1299 cells by GSPs is mediated through the
activation of procaspase-9, caspase-3 and PARP proteins.
Treatment of A549 and H1299 cells with GSPs for 48 h resulted
in a dose-dependent reduction in the levels of caspase-9 while
increasing the cleavage of caspases-9, caspase-3 and PARP
proteins compared with the vehicle-treated cells (Figure 3A).
The GSPs-induced activation of caspase-3 in A549 and H1299
cells also was determined using a colorimetric caspase-3 activity
assay. Treatment of both A549 and H1299 lung cancer cells with
GSPs for 48 h resulted in a significantly higher (p,0.05; p,0.001)
caspase-3 activity in a dose-dependent manner than that observed
in the vehicle-treated control cells (Figure 3B).
Treatment with the caspase-3 inhibitor (z-DEVD-fmk)
blocks GSPs-induced apoptosis of both A549 and H1299
cells
To further confirm that GSPs-induced activation of caspase-3 is
involved in the induction of apoptotic cell death of A549 and
H1299 human lung cancer cells, we determined whether the
Figure 1. GSPs induce apoptosis in non-small cell lung cancer cells. (A) In vitro treatment of A549 and H1299 cells with GSPs induces
apoptosis in a dose-dependent manner. Apoptotic cell death was analyzed using FACS analysis, and total percentage of apoptotic cells in A549 and
H1299 cells are summarized as mean 6 SD, n=3. Significant difference versus non-GSPs-treated controls:
*P,0.05;
"P,0.01;
{P,0.001. (B) Treatment
of A549 and H1299 cells with GSPs results in a dose-dependent reduction in the expression of anti-apoptotic proteins, Bcl-2 and Bcl-xl while
increasing the expression of the pro-apoptotic protein, Bax, as determined by western blot analysis. Data are representative of three independent
experiments with similar results.
doi:10.1371/journal.pone.0027444.g001
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the addition of the caspase-3-specific inhibitor (z-DEVD-fmk).
A549 and H1299 cells had been treated with GSPs with or without
z-DEVD-fmk (60 mmol/L) for 48 h. Cells were harvested and cell
death was assayed using Cell Death Detection ELISA kit following
the instructions of the manufacturer. As shown in Figure 3C (left
panel), treatment of A549 cells with GSPs at the concentrations of
60 and 80 mg/mL resulted in 31% and 49% apoptosis or cell
death respectively compared to 6.5% in non-GSPs-treated control
cells. The treatment of A549 cells with GSPs (60 or 80 mg/mL) in
the presence of z-DEVD-fmk resulted in only 14% and 17%
apoptosis, respectively, which clearly indicated that the presence of
caspase-3-specific inhibitor significantly blocked GSPs-induced
apoptotic cells death (P,0.001) in A549 cells. Similar results were
found when H1299 cells were treated with GSPs in the presence or
absence of z-DEVD-fmk, as shown in Figure 3C (right panel).
These results indicate that GSPs-induced apoptosis of both A549
and H1299 human lung cancer cells is associated with the
activation of caspase-3.
GSPs induce G1 phase cell cycle arrest in NSCLC cells
Based on the preliminary studies where we observed a strong
growth inhibitory effect of GSPs on NSCLC cells, we then
determined the possible mechanism of anti-proliferative activity of
GSPs which may lead to apoptotic cell death. For this purpose the
effect of GSPs on cell cycle progression in A549 and H1299 cells
Figure 2. GSPs disrupt mitochondrial membrane potential in non-small cell lung cancer cells.( A&B ) Immunoblotting for cytochrome c
and Smac/DIABLO using cytosolic and mitochondrial fractions prepared from A549 and H1299 cells following treatment with indicated
concentrations of GSPs for 48 h. The blots were stripped and re-probed with anti-COX IV antibody to ensure equal mitochondrial protein loading as
well as to rule out cross-contamination of mitochondrial and cytosolic fractions. (C) Treatment of A549 and H1299 cells with GSPs induces loss of
mitochondrial membrane potential. Cells were treated with indicated doses of GSPs for 48 h. JC-1 dye-stained cell were analyzed by flow cytometry,
as described in Materials and Methods. Data are representative of two separate experiments with identical observations.
doi:10.1371/journal.pone.0027444.g002
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summarized in Figure 4, (Panels A–D), treatment of A549 cells
with GSPs resulted in a significant higher number of cells in the
G1 phase at all the concentrations used: 20 mg/mL (58.3%,
P,0.05), 40 mg/mL (67.9%, P,0.001) and 60 mg/mL (75.5%,
P,0.001) compared to the non-GSPs treated control (52.7%). As
indicated in Figure 4 (Left panels A–D), the dose-dependent effect
of GSPs on G1 arrest in A549 cells was largely at the expense of
cells in S phase with a minimal change in G2-M cell population
compared with the non-GSPs-treated control cells (Panel A).
Similar effect of GSPs on G1 phase arrest was also found in H1299
cells (Figure 4, right panels A–D). The results of cell cycle
Figure 3. Induction of apoptosis in lung cancer cells by GSPs is mediated through caspase-3 activation.( A) Treatment of A549 and
H1299 cells with GSPs reduces the level of caspase-9 while increases the activation/cleavage of caspase-9, caspase-3 and PARP in a dose-dependent
manner. Cells were treated with varying concentrations of GSPs (0, 20, 40, 60 and 80 mg/mL) for 48 h, thereafter cells were harvested, cell lysates
prepared and subjected to western blot analysis to detect the levels of caspase-9, cleaved caspase-9, caspase-3 and PARP. A representative blot is
shown from three independent experiments with similar results. (B) The caspase-3 activity in cell lysates from the samples of Panel A was measured
using a colorimetric protease assay (ApoTarget Kit). GSPs treatment to A549 and H1299 cells increases the activity of caspase-3 dose-dependently.
Significant difference versus non-GSPs treatment group,
"P,0.01 and
*P,0.001. (C) The effect of GSPs (60 and 80 mg/mL) on apoptosis of A549 and
H1299 cells was determined after 48 h in the absence or presence of 60 mmol/L of the caspase-3 inhibitor (z-DEVD-fmk). The content of apoptotic
cells was determined using cell death detection ELISA kit, as detailed in Materials and Methods. The cells treated with z-DEVD-fmk blocked the GSPs-
induced apoptosis in A549 and H1299 cells. The percentage of apoptotic cells in different treatment groups was summarized and data are presented
as mean 6 SD from two repeated experiments. Significant inhibition by caspase-3 inhibitor versus GSPs alone treated cells,
*P ,0.001. CI=caspase-3
inhibitor, C=control, without any treatment.
doi:10.1371/journal.pone.0027444.g003
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which indicated the significant arrest of A549 and H1299 cells in
G0–G1 phase after GSPs treatment.
GSPs decrease the expressions of G1 regulatory proteins
of Cdks and cyclins in NSCLC cells
Studies have shown that Cdks and cyclins play crucial roles in
the regulation of cell cycle progression [21], therefore we
determined the effect of GSPs on the protein levels of the Cdks
and cyclins which are negatively regulated by Cdki (Cip1/p21 and
Kip1/p27) during G1 phase cell cycle progression. As shown in
Figure 5 (Panel A), treatment of A549 cells with GSPs resulted in a
marked decrease in the expression of Cdk2, Cdk4 and Cdk6 in a
dose-dependent manner at 48 h after GSPs treatment. A strong
reduction in Cdks was observed at the doses of 40–80 mg/mL
concentrations of GSPs. Similarly, a marked reduction in the
expression of cyclins D1, D2 and E was observed in a dose-
dependent manner. Identical effect of GSPs was also found when
H1299 cells were treated with GSPs and under identical
conditions (Figure 5A, right panels).
GSPs increase the expression of Cdki (Cip1/p21 and Kip1/
p27) in NSCLC cells
The Cdki regulate the progression of cells in the Go/G1 phase
of the cell cycle and induction of Cip1/p21 and Kip1/p27 causes
a blockade of the G1 to S transition, thereby resulting in a Go/G1
phase arrest of the cell cycle [22]. The loss of Cdki in human
cancers leads to uncontrolled cell proliferation [23]. In this
context, our results revealed that treatment of human NSCLC
cells, A549 and H1299, with varying concentrations of GSPs (0,
20, 40, 60 and 80 mg/mL) for 48 h resulted in a dose-dependent
increase in protein expression of Kip1/p27 and Cip1/p21
(Figure 5 B). The GSPs-induced increase in inhibitory Cdki
proteins may have a role in blockade of A549 and H1299 cells in
G1 phase. These changes in protein expression were not due to
differences in the amount of proteins loaded on the gels as the
equivalent protein loading was confirmed by probing stripped
blots for b-actin, as shown in Figure 5B.
GSPs increase Cdk-Cdki binding in NSCLC cells
As GSPs induce the expression of Cdki in both A549 and
H1299 cells, and since the induction of the Cdki has been shown
to result in an increased interaction with Cdks leading to a
decrease in their kinase activity [24], we next determined whether
GSPs promote the interaction between Cdki and Cdk. To assess
this effect, Cip1/p21 and Kip1/p27 were immunoprecipitated
from total cell lysates of A549 and their binding with Cdk2, Cdk4
and Cdk6 was assessed using western blot analysis. As compared to
vehicle treated controls, treatment with GSPs was found to
enhance the binding of Cdk2, Cdk4 and Cdk6 with Cip1/p21 and
Kip1/p27 (Figure 5C). These results suggest that an increased
interaction between Cdki with Cdks plays an important regulatory
role in the GSPs-induced G1 arrest of cell cycle progression in
human non-small cell lung cancer cells, possibly through the
decrease in their Cdk kinase activity.
Administration of GSPs by oral gavage inhibits the
growth of tumor xenografts: GSPs are non-toxic to mice
Next, we determined the effect of GSPs on A549 and H1299
xenografts growth in immuno-compromised athymic nude mice.
Three different doses of GSPs, i.e., 50, 100 and 200 mg GSPs/kg
body weight of mice were used and the effects on the growth of the
tumors were monitored. The body weights and consumption of
diet and water per animal in each treatment group was recorded
on weekly basis. The average body weight of the GSPs-treated and
non-GSPs-treated control mice remained identical throughout the
duration of the experiment protocol (Figure 6A). The daily
consumption of diet or drinking water by the mice in each group
was also almost identical (data not shown) and the mice that were
treated with GSPs did not exhibit impaired movement and posture
or any other sign of physical toxicity. These data suggest that
administration of GSPs by oral gavage at the concentrations used
in these studies is not associated with visible toxicity in laboratory
animals.
Periodic measurement of the tumor xenograft volume indicated
that the treatment with GSPs, particularly with the doses of 100
and 200 mg GSPs/kg body weight, resulted in reduced growth of
both the A549 and H1299 lung cancer xenografts throughout the
duration of the experiment. As can be seen in Figure 6B (left
panel), the GSPs-induced inhibition of A549 xenograft tumor
volume was 51% in mice administered GSPs at a concentration of
100 mg/kg body weight and 75% (P,0.001) in the mice
administered GSPs at a concentration of 200 mg/kg body weight.
Significant inhibition of the H1299 xenograft tumors also was
observed after the treatment of mice with GSPs (Figure 6B, right
panel).
At the termination of the experiment on the 58
th day of the
experiment, the wet weight of the tumor/mouse in each treatment
group was recorded. As shown in Figure 6C (left panel), the wet
weight of the A459 xenograft tumor/mouse was significantly lower
in the mice administered GSPs than in the mice that did not
receive GSPs. The wet weight of the A549 tumors was 14% lower
in mice administered 50 mg GSPs/kg body weight; 45% lower
(P,0.001) in mice administered 100 mg GSPs/kg body weight;
and 71% lower (P,0.001) in mice administered in 200 mg GSPs/
kg body weight compared with non-GSPs-treated control mice.
Administration of GSPs at the same concentrations also resulted in
a reduction in the wet weight of the H1299 tumor xenografts
(Figure 6C, right panel). The wet weight of the H1299 tumors was
15% lower (not significant) in mice administered 50 mg GSPs/kg
body weight; 39% lower (P,0.01) in mice administered 100 mg
GSPs/kg body weight; and 62% lower (P,0.001) in mice
administered in 200 mg GSPs/kg body weight.
GSPs inhibit the growth of A549 and H1299 tumor
xenografts through the enhancement of apoptotic cell
death of tumor cells
To determine if administration of GSPs by gavage inhibits the
growth of tumor xenografts by enhancing the apoptosis of the lung
tumor cells in vivo, the xenograft tumors were subjected to
TUNEL-positive staining. As shown in Figure 7A, the percentages
of TUNEL-positive cells were significantly higher (P,0.001) in the
Figure 4. Effect of GSPs on cell cycle progression of A549 and H1299 cells. Cells were treated either with vehicle (0.1% DMSO in medium) or
20, 40 and 60 mg/mL doses of GSPs in complete medium. After 48 h of treatment, cells were harvested and digested with RNase. Cellular DNA was
stained with propidium iodide and flow cytometric analysis was performed to analyze the cell cycle distribution, as detailed in the Materials and
Methods. (A–D) Cell cycle distribution in A549 (left panels) and H1299 (right panels) cells with the treatment of various concentrations of GSPs. (E)
Data from the cell cycle distribution were summarized and presented as the mean 6 SD of three independent experiments. Statistically significant
versus non-GSPs treated control group,
"P ,0.05 and
*P ,0.01.
doi:10.1371/journal.pone.0027444.g004
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compared to percentages of TUNEL-positive cells in the xenograft
tumors in the control mice that did not receive GSPs. The
percentage of TUNEL-positive cells was comparatively higher in
the A549 xenograft tumors than the H1299 xenograft tumors.
To further determine the mechanisms involved in the GSPs-
mediated induction of apoptosis in vivo tumor cells, we examined
tumor xenograft samples from each of the treatment groups for the
expressions of pro- and anti-apoptotic proteins of the Bcl-2 family
using western blot analysis. As shown in Figure 7B, the levels of the
anti-apoptotic proteins, Bcl-2 and Bcl-xl, were lower in the A459
and H1299 xenograft tumors from mice treated with GSPs than in
the tumors in control mice that did not receive GSPs, whereas the
levels of the pro-apoptotic protein, Bax, were higher. The cleavage
of caspase-3 and caspase-9 proteins was markedly higher in the
tumor from the GSPs-treated mice than the control mice.
Similarly, the cleavage of PARP protein was enhanced, as shown
in Figure 7C.
Additionally, we determined whether GSPs treatment also
affects the tumor cell proliferation potential in the A549 and
H1299 tumor xenografts. As summarized in Figure 7D, immuno-
histochemical detection analysis of PCNA-positive cells in tumor
xenograft tissues indicated that the percentage of proliferating cells
was significantly lower in both the A549 (P,0.001) and H1299
(P,0.01) tumor xenografts from GSPs-treated mice than the
xenograft tumors from the control mice.
Administration of GSPs decreases the expressions of G1
regulatory proteins of Cdks and cyclins while increases
the levels of Cdk inhibitory proteins in tumor xenograft
tissues of NSCLC cells
As the inhibitory effect of GSPs on the tumor xenograft growth
of A549 and H1299 cells was identical, we selected the tumor
tissues of A549 cells for further analyses of cell cycle regulatory
proteins. As shown in Figure 8A, treatment of mice with GSPs
resulted in a marked decrease in the expression of Cdk2, Cdk4 and
Cdk6 compared to the tumors from non-GSPs-treated mice in a
dose-dependent manner. Similarly, a marked reduction in the
expression of cyclins D1, D2 and E was also observed.
As the Cdki regulate the progression of cells in the Go/G1
phase of the cell cycle, we also examined the effect of GSPs on the
levels of Cdk inhibitory proteins in tumor xenograft tissues from
each treatment group. Western blot analysis revealed that
administration of GSPs resulted in a dose-dependent increase in
protein expression of Kip1/p27 and Cip1/p21 (Figure 8B). The
GSPs-induced increase in the levels of Cdki proteins may have a
role in controlling the cell cycle progression and that may have
resulted in suppression of tumor growth.
Discussion
Chemotherapy offers a promising strategy for control of cancer.
Several phytochemicals including dietary plant products have
been shown to have anti-carcinogenic properties. GSPs represent
one such phytochemicals and have been shown to have anti-
carcinogenic activity in different organs [10–12,25,26]. We have
shown previously that long-term dietary feeding of GSPs
supplemented with AIN76A control diet of laboratory animals
does not show apparent signs of toxicity [10,11]. In the present
study, we further verify that long-term administration of GSPs by
oral gavage also does not induce any visible sign of toxicity in
mice. Similarly, in vitro studies indicate that GSPs exhibit anti-
proliferation or cytotoxic effects against tumor cells, but do not
exhibit toxic effects on the growth and viability of normal (non-
neoplastic) cells in culture [11,12,25]. Previously we have shown
that treatment of both A549 and H1299 human non-small cell
lung cancer cells with GSPs resulted in inhibition of cell
Figure 5. Effect of GSPs on G1 phase cell cycle regulatory
proteins in A549 and H1299 cells. The cells were treated with either
vehicle (0.1% DMSO in medium) or GSPs (20, 40, 60 and 80 mg/mL) for
48 h and thereafter harvested, cell lysates prepared and then subjected
to SDS-PAGE followed by Western blot analysis, as described in
Materials and methods. Effect of GSPs was determined on the following:
(A) the expression of cyclin D1, cyclin D2 and cyclin E, and the
expression levels of Cdk2, Cdk4 and Cdk6; and (B) the expression of
Kip1/p27 and Cip1/p21. b-actin was used to verify equal loading of the
samples. Representative blots are shown from three independent
experiments with almost identical results. (C) In binding assay, Cip1/p21
and Kip1/p27 were immunoprecipitated using specific antibody from
total protein lysates followed by SDS-PAGE and western blot analysis for
Cdk2, Cdk4 and Ckd6 as detailed in Materials and methods. IP,
immunoprecipitation; IB, immunoblotting.
doi:10.1371/journal.pone.0027444.g005
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GSPs were not observed in normal human bronchial epithelial
cells [11,12]. Induction of apoptosis is considered as one of the
possible mechanisms of inhibition of cancer development, and
many therapeutic agents have been shown to act through the
induction of apoptosis in their inhibition or blockade of the
carcinogenic process [27–29]. Some evidence indicates that
apoptosis may represent a protective mechanism against neoplastic
development by eliminating genetically damaged cells or those
cells that have improperly been induced to proliferate by factors
such as carcinogens [30,31].
Experimental evidence suggests that apoptosis can be mediated
by several different pathways and that there are numerous
regulatory molecules associated with these pathways. The proteins
of the Bcl-2 family include both pro- and anti-apoptotic members
that elicit opposing effects on mitochondria [15,32,33]. Enhance-
ment of pro-apoptotic Bax over Bcl-2 proteins can enhance the
permeability of the mitochondrial membrane, which in turn results
in the release of apoptogenic factors. Repression of anti-apoptotic
members of this family, including Bcl-2 and Bcl-xl, preserves the
integrity of the mitochondria. This blocks the release of soluble
inter-membrane factors such as cytochrome c that activate the
effectors of apoptosis [34]. In this study, we found that treatment
of the NSCLC cells with GSPs up-regulate the pro-apoptotic Bax
protein and down-regulate the anti-apoptotic proteins Bcl-2 and
Bcl-xl and that this occurs in both A549 and H1299 cells (Figure 1).
The alteration in the Bax/Bcl-2 ratio is critical for apoptosis and
causes the release of cytochrome c and Smac/DIABLO from
mitochondria into the cytosol after the loss of mitochondrial
membrane potential [15,16]. Cytosolic cytochrome c can bind to
Apaf-1 and activate caspase-9 in the apoptosomes in response to
diverse inducers of cell death [17,35]. Activation of caspase-9 leads
Figure 6. Administration of GSPs by gavage inhibits the growth of lung tumor xenografts in mice. Each mouse was s.c. implanted with
either 2610
6 A549 or H1299 cells mixed with Matrigel on the right flank. Twenty-four h later, mice were given either PBS (100 mL) or GSPs (50, 100 or
200 mg/kg body weight in 100 mL PBS) by gavage 5 days/week. (A) Change in body weight of mice during the 8 weeks study was monitored. The
body weights of the control and GSPs-fed mice did not differ significantly throughout the experiment protocol. (B) Average tumor volume 6SD/
mouse (mm
3) in each group. (C) Tumors were harvested at the termination of the experiment, and the wet weight of the tumor/mouse in grams in
each group is reported as mean 6 SD. Statistical significance of difference between control and GSPs-fed groups was analyzed by one-way ANOVA
followed by Bonferroni t test. n=10. Statistical significance vs non-GSPs-fed controls,
"P,0.05;
{P,0.01;
*P,0.005.
doi:10.1371/journal.pone.0027444.g006
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apoptosis [15,35]. GSPs also result in an increase in the release of
cytochrome c and Smac/DIABLO in cytosols (Figure 2), activa-
tion of caspase-9 and finally an increase in the activation or
cleavage of caspase-3 and PARP (Figure 3). The involvement of
GSPs-induced increase in activation of caspase-3 and its effect on
apoptosis was further confirmed by measuring its activity and
induction of apoptotic cell death by cell death detection ELISA.
The blockade of GSPs-induced apoptosis in A549 and H1299 cells
by the addition of the caspase-3 inhibitor (z-DEVD-fmk)
Figure 7. Administration of GSPs by gavage induces apoptosis
in tumor xenograft cells. (A) The data on terminal deoxynucleotidyl
transferase-mediated nick-end labeling (TUNEL)-positive cells in tumor
xenograft tissues from GSPs-treated and GSPs-untreated samples are
summarized. (B) GSPs inhibit the expression of anti-apoptotic proteins
while increases the expression of pro-apoptotic protein in A549 and
H1299 xenograft tissues. (C) GSPs enhance the activation of caspase-9,
caspase-3 and PARP proteins in tumor xenografts. Tumor lysates were
prepared from the tumors collected at the termination of the
experiment and subjected to western blot analysis, as described in
Materials and methods. Representative blots are presented from the
independent experiments from at least six tumors from six different
mice per group with identical observations. (D) Analysis of PCNA-
positive cells for proliferation index. Immunohistochemical data in
terms of percentage of positive cells (TUNEL-positive or PCNA-positive)
are summarized and presented as mean 6SD of 6–7 tumor samples
from each group. Statistical significance versus non-GSPs-fed controls,
{P,0.01;
*P,0.001.
doi:10.1371/journal.pone.0027444.g007
Figure 8. Effect of dietary GSPs on G1 phase cell cycle
regulatory proteins in xenograft tissues. The A549 tumor
xenograft tissues were harvested at the termination of the experiment,
and tumor lysates were subjected to the analyses of cell cycle proteins
of G1 phase using Western blot analysis, as described in Materials and
Methods. Effect of GSPs was determined on the following: (A) the
expression of cyclin D1, cyclin D2 and cyclin E, and the expression levels
of Cdk2, Cdk4 and Cdk6; and (B) the expression of Cdk inhibitory
proteins, Kip1/p27 and Cip1/p21. b-actin was used to verify equal
loading of the samples. Representative blots are presented from the
independent experiments from at least six tumors from six different
mice per group with identical expression levels of proteins.
doi:10.1371/journal.pone.0027444.g008
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apoptosis.
It has been recognized that control of cell cycle progression in
cancer cells is an effective strategy to inhibit tumor growth [22,36]
as the molecular analyses of human cancers have revealed that cell
cycle regulators are frequently deregulated in most of the common
malignancies [37,38]. Our in vitro data demonstrate that treatment
of A549 and H1299 cells with GSPs induces G1 phase arrest of cell
cycle progression (Figure 4) indicating that one of the mechanisms
by which GSPs inhibit the proliferation of lung cancer cells is
inhibition of cell cycle progression. Our studies demonstrate a
marked decrease in the expressions of cyclins D1, D2 and E, and
Cdk2, Cdk4 and Cdk6 in both A549 and H1299 cells dose-
dependently on GSPs treatment suggests the disruption of the
uncontrolled cell cycle progression of human NSCLC cells
(Figure 5) and that the GSPs-induced G1 arrest is mediated
through the up-regulation of cyclin-dependent kinase inhibitory
proteins, Cip1/p21 and Kip1/p27, which enhances the formation
of heterotrimeric complexes with the G1/S Cdks and cyclins
thereby resulting in inhibition of their activity.
Uncontrolled cell division depends on the activation of cyclins,
which bind to Cdk to induce cell cycle progression towards S
phase. Cdk kinase activity is one of the major causes of cancer
progression, and their functions are tightly regulated by Cdki, such
as, Cip1/p21 and Kip1/p27 proteins. Cip1/p21 is a universal
inhibitor of Cdk(s) and Kip1/p27 is commonly up-regulated in
response to anti-proliferative signals [39]. The increased expres-
sion of G1 cyclins in cancer cells provides them an uncontrolled
growth advantage because most of these cells either lack Cdki,
harbor nonfunctional Cdki, or Cdki expression is not at a sufficient
level to control Cdk-cyclin activity [38,40]. Consistent with these
reports, the increased expressions of Cdkis together with decreased
expression of cyclins and Cdks on the GSPs treatment to A549 and
H1299 cells suggest that GSPs might be effective as a
chemotherapeutic agent for the treatment of non-small cell lung
cancers.
Our in vivo study provides further evidence that administration
of GSPs by gavage inhibits the growth of both A549 and H1299
tumor xenografts by inducing cell death and without any apparent
sign of toxicity in athymic nude mice (Figures 6 and 7). Further,
consistent with the findings in cell culture model, an increase in the
levels of pro-apoptotic protein Bax, and cleaved caspase-9,
caspase-3 and PARP proteins were also observed in the tumors
of GSPs-treated group compared to the control mice which were
not given GSPs by gavage (Figure 7). These results also indicate
the inhibition of growth of lung tumor xenograft through
increased apoptosis of tumor cells and inhibition of tumor cell
proliferation in GSPs-treated mice.
It is reasonable to consider whether the chemotherapeutic effect
of GSPs examined in an animal model can be translated in human
system. For appropriate conversion of the doses of chemopreven-
tive or chemotherapeutic agent from animal studies to humans,
the body surface area normalization method has been recom-
mended [41]. In the present study, maximum dose of GSPs by oral
gavage was given 200 mg/kg body weight of the mouse. Based on
this information, the human equivalent dose of GSPs was
calculated using the following formula:
Human equivalent dose mg=kg ðÞ ~
Animal dose mg=kg ðÞ X
Animal Km factor
Human Km factor
(Km factor for mouse=3; Km factor for adult human=37).
If, the body weight of a normal standard person is considered to
be 70 Kg, then 1.13 g GSPs will be required for a healthy person/
day to produce same level of anti-lung carcinogenic effects as
observed in mice, which seems reasonable, affordable and
attainable.
In summary, the novelty of this study lies in the analysis of
chemotherapeutic effects of GSPs on additional new molecular
targets of NSCLC cells using both in vitro and in vivo models. This
detailed and systematic study revealed that GSPs induce apoptosis
of human non-small cell lung cancer cells by loss of mitochondrial
membrane potential, which was not reported earlier in this model.
The present findings provide pre-clinical data suggesting that
grape seed proanthocyanidins have the potential to be developed
as a pharmacologically safe agent either alone or in combination
with other drugs for the treatment of non-small cell lung cancers in
humans.
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